{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenomas&page=2",
    "query": {
      "condition": "Adenomas",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenomas&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T05:51:34.815Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02611024",
      "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Glioblastoma",
        "Soft Tissue Sarcoma (Excluding GIST)",
        "Endometrial Carcinoma",
        "Epithelial Ovarian Carcinoma",
        "Mesothelioma",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "SCLC",
        "Gastric Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Carcinoma",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2016-05-06",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 4,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611024"
    },
    {
      "nct_id": "NCT01043523",
      "title": "Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Neoplasms",
        "Adenoma",
        "Carcinoma",
        "Liver Abscess"
      ],
      "interventions": [
        {
          "name": "Gadoxetic Acid Disodium (Eovist, BAY86-4873)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Months to 18 Years"
      },
      "enrollment_count": 52,
      "start_date": "2009-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • New York, New York • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cinncinati",
          "state": "Ohio"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01043523"
    },
    {
      "nct_id": "NCT03784924",
      "title": "EDRN Prostate MRI Biomarker Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PSA",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "MRI prostate",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 950,
      "start_date": "2019-02-04",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784924"
    },
    {
      "nct_id": "NCT04569591",
      "title": "DDAVP for Pituitary Adenoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cushing's Disease",
        "Pituitary Adenoma"
      ],
      "interventions": [
        {
          "name": "Desmopressin acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "8 Years to 99 Years"
      },
      "enrollment_count": 22,
      "start_date": "2026-03-09",
      "completion_date": "2028-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04569591"
    },
    {
      "nct_id": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Microsatellite Stable Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Cervical Cancer",
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Melanoma Stage IV",
        "Merkel Cell Carcinoma of Skin",
        "Mesothelioma",
        "Non-small Cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma (CSCC)",
        "Urothelial Carcinoma Bladder",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "VET3-TGI",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "KaliVir Immunotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-09-16",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06444815"
    },
    {
      "nct_id": "NCT00582660",
      "title": "Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenoma",
        "Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2001-12",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-15",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582660"
    },
    {
      "nct_id": "NCT00604461",
      "title": "Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Carboplatin, Bevacizumab and Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2007-10",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00604461"
    },
    {
      "nct_id": "NCT06342440",
      "title": "Early Detection of Advanced Adenomas and Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Polyp",
        "Colorectal Adenocarcinoma",
        "Colorectal Disorders",
        "Colorectal Dysplasia",
        "Colorectal Cancer Stage I",
        "Colorectal Cancer Stage II",
        "Colorectal Cancer Stage III",
        "Colorectal Cancer Stage IV",
        "Colorectal Neoplasms Malignant",
        "Colorectal Serrated Adenocarcinoma",
        "Colorectal Adenoma With Severe Dysplasia",
        "Colorectal Adenoma With Mild Dysplasia",
        "Colorectal Adenoma With Moderate Dysplasia",
        "Colorectal Adenoma and Carcinoma 1",
        "Colorectal Adenomatous Polyp",
        "Colorectal Adenocarcinoma Metastatic in the Liver"
      ],
      "interventions": [
        {
          "name": "DENEB",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2020-03-15",
      "completion_date": "2028-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 2,
      "location_summary": "Monrovia, California • San Diego, California",
      "locations": [
        {
          "city": "Monrovia",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06342440"
    },
    {
      "nct_id": "NCT07361874",
      "title": "IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Autonomous Cortisol Secretion (MACS)",
        "Autonomous Cortisol Secretion (ACS)",
        "Subclinical Cushing's",
        "Mild Autonomous Cortisol Excess"
      ],
      "interventions": [
        {
          "name": "Intervention 1: Adrenalectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Intervention 2: Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2026-03-05",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07361874"
    },
    {
      "nct_id": "NCT05107674",
      "title": "A Study of NX-1607 in Adults With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer, Epithelial",
        "Gastric Cancer",
        "GastroEsophageal Junction (GEJ) Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic or Unresectable Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Malignant Pleural Mesothelioma (MPM)",
        "Triple Negative Breast Cancer (TNBC)",
        "Metastatic Urothelial Carcinoma",
        "Cervical Cancer",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Richter Transformation",
        "Microsatellite Stable Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "NX-1607",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nurix Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 345,
      "start_date": "2021-09-29",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-07-23T05:51:34.815Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107674"
    }
  ]
}